

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM813803

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Lucira Health, Inc.		04/20/2023	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Pfizer Inc.		
Street Address:	66 Hudson Boulevard East		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10001-2192		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 3			
Property Type	Number	Word Mark	
Registration Number:	6651374	LUCIRA	
Registration Number:	6442613	LUCIRA	
Registration Number:	6907400	LUCIRA	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Email:	DEADLINESIPNYO@Pfizer.com		
Correspondent Name:	Richard A. Friedman		
Address Line 1:	66 Hudson Boulevard East		
Address Line 4:	New York, NEW YORK 10001-2192		
NAME OF SUBMITTER:	Richard A. Friedman		
SIGNATURE:	/RAF/		
DATE SIGNED:	05/30/2023		
Total Attachments: 7			
source=LUCIRA - Trademark Assignment Agreement executed#page1.tif			
source=LUCIRA - Trademark Assignment Agreement executed#page2.tif			
source=LUCIRA - Trademark Assignment Agreement executed#page3.tif			
source=LUCIRA - Trademark Assignment Agreement executed#page4.tif			
source=LUCIRA - Trademark Assignment Agreement executed#page5.tif			

CH \$90.00 6651374

source=LUCIRA - Trademark Assignment Agreement executed#page6.tif

source=LUCIRA - Trademark Assignment Agreement executed#page7.tif

TRADEMARK ASSIGNMENT

THIS TRADEMARK ASSIGNMENT, dated as of April 20, 2023 (this "Assignment"), is by and between Lucira Health, Inc., a Delaware corporation ("Assignor") and Pfizer Inc., a Delaware corporation ("Assignee").

W I T N E S S E T H:

WHEREAS, Assignor and Assignee have entered into an Asset Purchase Agreement, dated as of April 12, 2023 as amended by that certain Amendment, dated as of April 18, 2023 (the "Purchase Agreement"), pursuant to which, among other things, Assignor has agreed to sell or cause to be sold to Assignee and Assignee has agreed to purchase from Assignor certain assets, as more fully described in the Purchase Agreement and upon the terms and conditions set forth therein;

WHEREAS, the Bankruptcy Court entered the Sale Order on April 19, 2023, approving the sale of the Transferred Assets to Assignee on the terms set forth in the Purchase Agreement and in the Sale Order; and

WHEREAS, pursuant to the Purchase Agreement, Assignor wishes to assign to Assignee, and Assignee wishes to assume from Assignor, the Trademarks that are listed on Schedule A (the "Transferred Trademarks").

NOW, THEREFORE, in consideration of the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and upon the terms and subject to the conditions set forth herein, the parties hereto hereby agree as follows:

1. Definitions. Capitalized terms used but not defined herein shall have the respective meanings ascribed to them in the Purchase Agreement.

2. Assignment. Assignor hereby irrevocably and unconditionally grants, sells, conveys, assigns, transfers and delivers to Assignee all of Assignor's right, title and interest in and to the Transferred Trademarks, including the goodwill and all common law rights associated therewith, together with all rights and remedies related to past, present and future infringement thereof and rights to protection of interests related thereto under all applicable Laws; provided that, with respect to any United States intent-to-use trademark application set forth on Schedule A, the transfer of such application accompanies, pursuant to the Purchase Agreement, the transfer of Assignor's business, or that portion of the business to which the Trademark pertains, and that business is ongoing and existing. Assignor hereby authorizes the respective trademark office or Governmental Entity in each jurisdiction to issue any and all registrations or other governmental grants or issuances that may be granted upon any of the Transferred Trademarks that are listed on Schedule A in the name of Assignee, as the assignee to the entire interest therein. Assignor further consents to the recordation of this Assignment by Assignee with the respective trademark office or Governmental Entity in each jurisdiction.

3. No Modification of the Purchase Agreement. Nothing contained herein shall release Assignor or Assignee from any of their respective obligations under the Purchase Agreement and the Sale Order or in any way supersede, enlarge, diminish, limit, amend or modify any of the representations, warranties, indemnities, covenants or agreements of such parties set forth in the Purchase Agreement or the Sale Order. In the event of any conflict or inconsistency between the terms of the Purchase Agreement and the terms hereof, the terms of the Purchase Agreement, as approved by the Sale Order, shall govern.

4. General Provisions. Article XII of the Purchase Agreement is hereby incorporated by reference herein *mutatis mutandis*.

[Signature Page Follows]

IN WITNESS WHEREOF, Assignor and Assignee have executed this instrument as of the date and year first written above.

LUCIRA HEALTH, INC.

By: *Erik T. Engelson*
Name: Erik T. Engelson
Title: Chief Executive Officer

IN WITNESS WHEREOF, Assignor and Assignee have executed this instrument as of the date and year first written above.

PFIZER INC.

DocuSigned by:

Latif Akintade

By: _____

Name: **Latif Akintade**

Title: **SVP, Patient and Health Impact**

[Signature Page to Trademark Assignment Agreement]

**TRADEMARK
REEL: 008086 FRAME: 0512**

Schedule A

Transferred Trademarks

Trademark/Office Name	Country	App# No	App# Date	Reg. No	Reg. Date	Classification	Status
LUCIRA	United States	88398691	23 Apr 2019	88398691	22 Nov 2022	Class 44: Medical diagnostic testing, monitoring and reporting services First Use: 30 Jun 2019 / First Use in Commerce: 30 Jun 2019	Registered
LUCIRA	United States	88981951	23 Apr 2019	6442613	3 Aug 2021	Class 05: Medical diagnostic reagents; reagents for medical use in DNA-based and RNA-based disease detection First Use: 31 Dec 2020 / First Use in Commerce: 31 Dec 2020	Registered
LUCIRA	United States	90594851	22 Mar 2021	6651374	22 Feb 2022	Class 05: Diagnostic test kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, COVID-19 First Use: 31 Dec 2020 / First Use in Commerce: 31 Dec 2020	Registered
LUCIRA	Canada	2072530	21 Dec 2020			Class 05: Medical diagnostic test kits; medical diagnostic reagents	Pending
LUCIRA	Dominican Republic	202261457	27 Oct 2022	294829	3 Jan 2023	Class 05: Medical diagnostic reagents; reagents for medical use in DNA-based and RNA-based disease detection Class 09: Downloadable computer software for use in reporting and communicating regarding medical diagnostic test results and medical diagnosis Class 45: Telemedicine and medical consulting services; medical diagnostic testing, monitoring and reporting services	Registered
LUCIRA	Hong Kong	305046110	4 Sep 2019	305046110	10 Jan 2020	Class 05: Medical diagnostic reagents; reagents for medical use in DNA-based and RNA-based disease detection	Registered
LUCIRA	Madrid Protocol Designated Jurisdictions: New Zealand	1495966	3 Sep 2019	1495966	31 Oct 2019	Class 05: Medical diagnostic reagents; reagents for medical use in DNA-based and RNA-based disease detection Class 09: Downloadable computer software for use in reporting and communicating regarding medical diagnostic test results and medical diagnosis Class 44: Telemedicine and medical consulting services; medical diagnostic testing, monitoring and reporting services	Registered

LUCIRA	New Zealand (via Madrid Protocol)	1133655	3 Sep 2019	1495966	4 Mar 2020	Class 05: Medical diagnostic reagents; reagents for medical use in DNA-based and RNA-based disease detection Class 09: Downloadable computer software for use in reporting and communicating regarding medical diagnostic test results and medical diagnosis Class 44: Telemedicine and medical consulting services; medical diagnostic testing, monitoring and reporting services	Registered
--------	---	---------	------------	---------	------------	--	------------

TRADEMARK
REEL: 008086 FRAME: 0515

RECORDED: 05/30/2023